Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
Updated guidelines recommend immediate antiretroviral treatment (ART) during acute HIV infection (AHI), but efficacy data on regimens during AHI are limited.



We provide final data on a prospective, single-arm 96-week open-label study of once-daily emtricitabine/tenofovir/efavirenz initiated during AHI. The primary endpoint was the proportion of responders with HIV RNA less than 200 copies/ml by week 24. We examined time to viral suppression, retention, and CD8 cell activation through week 96 in relation to baseline characteristics.



Between January 2005 and December 2011, 92 AHI participants enrolled. Most participants (78%) were men who have sex with men (MSM), and 42% were young MSM (18-25 years of age). Two participants withdrew leaving 90 patients for analysis. Eighty-one (90%) remained on therapy and achieved viral suppression to less than 200 copies/ml by week 24, and 71 (79%) to less than 50 copies/ml at week 48. The median time from ART initiation to suppression less than 200 copies/ml was 65 days (range 7-523) and to less than 50 copies/ml was 105 days (range 14-523). The frequency of immune activation declined from a median of 67% to 16% through week 96. Retention on study was maintained in 92% of participants at week 48 and in 83% through week 96. Among 75 participants retained through week 96, 92% were suppressed to less than 50 copies/ml. Among 39 young MSM, 79% completed a week 96 visit and 67% were suppressed at week 96.



ART during AHI resulted in rapid and sustained viral suppression with high rates of retention in care and on ART in this cohort including a large proportion of young MSM.
aDepartment of Medicine, UNC Institute for Global Health & Infectious Diseases bDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill cDepartment of Medicine, Division of Infectious Diseases dDepartment of Surgery eDuke Human Vaccine Institute, Duke University, Durham fLaboratory Corporation of America, Burlington, North Carolina gDepartment of Clinical Medicine, University of San Diego, San Diego, California, USA.
Cynthia L
CL
Gay
Sarah J
SJ
Willis
Anna B
AB
Cope
JoAnn D
JD
Kuruc
Kara S
KS
McGee
Joe
J
Sebastian
Amanda M
AM
Crooks
Mehri S
MS
McKellar
David M
DM
Margolis
Susan A
SA
Fiscus
Charles B
CB
Hicks
Guido
G
Ferrari
Joseph J
JJ
Eron
D000293:Adolescent; D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D048588:Benzoxazines / Q000008:administration & dosage*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003521:Cyclopropanes; D004338:Drug Combinations; D000068679:Emtricitabine / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D000072230:Sustained Virologic Response; D000068698:Tenofovir / Q000008:administration & dosage*; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D004338:Drug Combinations; D012367:RNA, Viral; D000068698:Tenofovir; D000068679:Emtricitabine; C098320:efavirenz
PLoS One. 2012;7(8):e43754
22952756
J Infect Dis. 2005 May 1;191(9):1403-9
15809897
J Int AIDS Soc. 2015 Dec 02;18(Suppl 6):20296
26639119
PLoS Med. 2012;9(3):e1001196
22479156
PLoS One. 2009;4(3):e4724
19266092
N Engl J Med. 2015 Aug 27;373(9):795-807
26192873
Lancet. 2013 Nov 2;382(9903):1515-24
24152938
J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):169-77
25590270
AIDS. 2011 Apr 24;25(7):941-9
21487250
PLoS One. 2011 May 10;6(5):e19617
21573003
JAMA Pediatr. 2016 Feb;170(2):125-31
26641367
AIDS. 2007 Aug 20;21(13):1723-30
17690570
MMWR Morb Mortal Wkly Rep. 2014 Feb 7;63(5):85-9
24500286
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7
10737796
J Exp Med. 2009 Jun 8;206(6):1253-72
19487423
Blood. 2010 Dec 16;116(25):5571-9
20837780
J Infect Dis. 2005 May 1;191(9):1410-8
15809898
AIDS. 2000 Oct 20;14(15):2333-9
11089621
J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):111-9
26761274
N Engl J Med. 2005 May 5;352(18):1873-83
15872202
PLoS One. 2010 Oct 12;5(10):e13310
20967271
AIDS Care. 2016 Sep;28(9):1177-80
26916991
AIDS. 2010 Jun 19;24(10):1598-601
20549847
Nat Rev Immunol. 2010 Jan;10(1):11-23
20010788
AIDS Res Hum Retroviruses. 2013 Jan;29(1):121-8
22839749
J Infect Dis. 2012 Jan 1;205(1):87-96
22180621
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):258-62
22692092